These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 25871584)

  • 1. Identification of a novel human circulating metabolite of tenofovir disoproxil fumarate with LC-MS/MS.
    Nye LC; Gray N; McClure M; Boffit M; Holmes E; Plumb RS; Wilson ID
    Bioanalysis; 2015; 7(6):643-52. PubMed ID: 25871584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability behaviour of antiretroviral drugs and their combinations. 4: Characterization of degradation products of tenofovir alafenamide fumarate and comparison of its degradation and stability behaviour with tenofovir disoproxil fumarate.
    Golla VM; Kurmi M; Shaik K; Singh S
    J Pharm Biomed Anal; 2016 Nov; 131():146-155. PubMed ID: 27589032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.
    Hummert P; Parsons TL; Ensign LM; Hoang T; Marzinke MA
    J Pharm Biomed Anal; 2018 Apr; 152():248-256. PubMed ID: 29433097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir.
    Brooks KM; Castillo-Mancilla JR; Blum J; Huntley R; MaWhinney S; Alexander K; Kerr BJ; Ellison L; Bushman LR; MacBrayne CE; Anderson PL; Kiser JJ
    J Antimicrob Chemother; 2019 Aug; 74(8):2360-2364. PubMed ID: 31081036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An LC-MS/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: Development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer.
    Xiao D; Ling KHJ; Tarnowski T; Majeed SR; German P; Kearney BP; Zhao Y; Chen YS; Ma L; Zhang T
    Anal Biochem; 2020 Mar; 593():113611. PubMed ID: 32035040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
    Taneva E; Crooker K; Park SH; Su JT; Ott A; Cheshenko N; Szleifer I; Kiser PF; Frank B; Mesquita PM; Herold BC
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1667-75. PubMed ID: 26711762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A LC/MS/MS method for determination of tenofovir in human plasma and its application to toxicity monitoring.
    Wiriyakosol N; Puangpetch A; Manosuthi W; Tomongkon S; Sukasem C; Pinthong D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 May; 1085():89-95. PubMed ID: 29635209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degradants of Tenofovir Disoproxil Fumarate Under Forced Yet Mild Thermal Stress: Isolation, Comprehensive Structural Elucidation, and Mechanism.
    Ranga M; Modini AK; Nallajarla AK; Doddipalla R; Kaliyaperumal M; Goswami A
    AAPS PharmSciTech; 2023 Jun; 24(6):139. PubMed ID: 37349667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [LC-MS/MS Determination of Tenofovir in Human Plasma and Its Bioequivalence].
    Chen ZH; Feng SY; Nan F; Yu Q; Liang MZ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):107-112. PubMed ID: 29737100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study.
    Cressey TR; Siriprakaisil O; Klinbuayaem V; Quame-Amaglo J; Kubiak RW; Sukrakanchana PO; Than-In-At K; Baeten J; Sirirungsi W; Cressey R; Drain PK
    BMC Infect Dis; 2017 Jul; 17(1):496. PubMed ID: 28705153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative pharmacokinetic and tolerability analysis of the novel orotic acid salt form of tenofovir disoproxil and the fumaric acid salt form in healthy subjects.
    Kim YK; Choi MJ; Oh TY; Yu KS; Lee S
    Drug Des Devel Ther; 2017; 11():3171-3177. PubMed ID: 29158663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assay development for determination of tenofovir in human plasma by solid phase analytical derivatization and LC-MS/MS.
    Podany AT; Sheldon C; Grafelman D; Ohnmacht CM
    Bioanalysis; 2015 Dec; 7(24):3085-95. PubMed ID: 26626536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid quantification of tenofovir in umbilical cord plasma and amniotic fluid in hepatitis B mono-infected pregnant women during labor by ultra-performance liquid chromatography/tandem mass spectrometry.
    Ma Z; Li S; He D; Wang Y; Jiang H; Zhou H; Jin J; Lin N
    Rapid Commun Mass Spectrom; 2020 May; 34(9):e8728. PubMed ID: 31960519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
    AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of efficiencies of selected sample extraction techniques for the analysis of selected antiretroviral drugs in human plasma using LC-MS.
    Sichilongo K; Mwando E; Sepako E; Massele A
    J Pharmacol Toxicol Methods; 2018; 89():1-8. PubMed ID: 28989077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous determination of tenofovir alafenamide and tenofovir in human plasma by LC-MS/MS and its application to pharmacokinetics study in clinic.
    Zhao L; Li Z; Zhou Z; Kang X; Fang B; Ma H; Ge Q
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jun; 1117():148-157. PubMed ID: 31031221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and bioequivalence study of emtricitabine/tenofovir disoproxil fumarate tablets in healthy Chinese subjects
.
    Lu C; Yang Y; Zhang Q; Zhou R; Liu Z; Hu W
    Int J Clin Pharmacol Ther; 2019 Dec; 57(12):623-632. PubMed ID: 31549623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability behaviour of antiretroviral drugs and their combinations. 3: Characterization of interaction products of emtricitabine and tenofovir disoproxil fumarate by mass spectrometry.
    Kurmi M; Singh DK; Tiwari S; Sharma P; Singh S
    J Pharm Biomed Anal; 2016 Sep; 128():438-446. PubMed ID: 27344633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability behaviour of antiretroviral drugs and their combinations. 2: Characterization of interaction products of lamivudine and tenofovir disoproxil fumarate by mass and NMR spectrometry.
    Kurmi M; Kushwah BS; Sahu A; Narayanam M; Singh S
    J Pharm Biomed Anal; 2016 Jun; 125():245-59. PubMed ID: 27042808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
    Ramanathan S; Custodio JM; Wei X; Wang H; Fordyce M; Dave A; Ling KH; Szwarcberg J; Kearney BP
    J Acquir Immune Defic Syndr; 2016 Jul; 72(3):281-8. PubMed ID: 26885802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.